|
|
Post by cardioltherapeutics on Jan 22, 2021 2:21:51 GMT
Cardiol Therapeutics
There are some pretty significant near term catalysts from Cardiol’s active COVID trials with the FDA, but I don’t think investors are giving enough credit to their high concentration Pharma-grade CBD product, Cortalex, that is currently selling in Canada’s largest drug store. CBD, in high concentration has proven incredibly effective for many ailments, one of them being childhood epilepsy, as referenced by Harvard University. The market for this in Canada alone is worth $100 million.
The team is led by some of the most qualified veterans in the medical world. This is not a cannabis company as many classify it - this is a groundbreaking BioTech company.
It's only closest comparable, sitting at a monstrous $4.1 billion market cap, is GW Pharma, who has had massive stock success after selling their high concentration CBD product in the U.S. for childhood epilepsy. GW however, unlike Cardiol, can not sell their product in Canada, as it is too expensive for the Government backed health care system.
One of Cardiol's biggest competitive advantages is it's proprietary process for purifying and concentrating CBD to pharmaceutical grade, through their partnership with Dalton Pharmaceuticals, an industry leader.
It would be wise to keep this one on the watchlist!
|
|
|
|
Post by JHam on Jan 22, 2021 2:31:43 GMT
Cardiol Therapeutics There are some pretty significant near term catalysts from Cardiol’s active COVID trials with the FDA, but I don’t think investors are giving enough credit to their high concentration Pharma-grade CBD product, Cortalex, that is currently selling in Canada’s largest drug store. CBD, in high concentration has proven incredibly effective for many ailments, one of them being childhood epilepsy, as referenced by Harvard University. The market for this in Canada alone is worth $100 million. The team is led by some of the most qualified veterans in the medical world. This is not a cannabis company as many classify it - this is a groundbreaking BioTech company. It's only closest comparable, sitting at a monstrous $4.1 billion market cap, is GW Pharma, who has had massive stock success after selling their high concentration CBD product in the U.S. for childhood epilepsy. GW however, unlike Cardiol, can not sell their product in Canada, as it is too expensive for the Government backed health care system. One of Cardiol's biggest competitive advantages is it's proprietary process for purifying and concentrating CBD to pharmaceutical grade, through their partnership with Dalton Pharmaceuticals, an industry leader. It would be wise to keep this one on the watchlist! Thanks for the heads up. It sounds promising. I’ll look into to it. Welcome to the board! |
|
|
|
Post by JHam on Jan 22, 2021 14:17:50 GMT
Did some digging into this one. The more I read up, the more I'm interested... Ticker: CRTPF (trades on the OTC); TSX - CRDL Market cap: 82.97M Float: 29.02M (o/s: 32.81M - 41.8M fully diluted) CoH: $16M Debt: none Insider ownership: 20% Pharmaceutical Partners & Research Collaborator ownership: 8% I just read through the corporate presentation, and watched the last investor conference presentation. There is a lot to like and I will probably be starting a position this morning. Some highlights: - Lead candidate, CardiolRx, is their formulation of Cannabidiol used to treat Acute Myocarditis
- Plan to submit P2 IND for Acute Myocarditis in Q1 2021
- Acute Myocarditis has a small population therefore giving them Orphan status eligibility
- GW Pharma developed their own formulation of Cannabidiol (similar to CardiolRx) for treatment of rare forms of epilepsy. Now a $4B company
- Patient population for Acute Myocarditis is twice the size of the epilepsy market GW Pharma targets
- P2/3 COVID trial using CardioRx to examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD) - ongoing. Full enrollment anticipated for 2Q 2021. Could have a label claim (aka hit the market) by 2H 2021 for a large population
- In October 2020 partnered and launched Cortalex (their high concentration, 99.5% pure, THC-free, CBD formulation) for medicinal use with largest national pharmacy chain in Canada (more than 1,300 stores). The cannabinoid market exceeds $600M in Canada alone. Should have first sales numbers in Q1 2021. Should start to provide cashflow. CEO thinks it will transform company for shareholders.
- Insiders strongly aligned with shareholder interests. Insiders continue to participate in capital raises, including a $17M raise in spring of 2020 of which insiders (including the CEO) accounted for $6M of that
-Plan to up-list to the NASDAQ as soon as possible
- GW Pharma was revalued at 10x after up-listing. Went from a $100M market cap to a $1B market cap in the months after up-listing. Now $4B.
- Steve Grasso, of CNBC fame, recently came to them as an advisor and is working to help facilitate their up-list to the NASDAQ and help expand their reach to the broader markets. CEO said he has been giving the company and BoD "amazing" advice.January corporate presentation: www.cardiolrx.com/wp-content/uploads/2021/01/Cardiol-Therapeutics-Website-Presentation-Janaury-2021.pdfRenmark investor summit presentation (December): talk-deck.com/playback/t62jl |
|
|
|
Post by JHam on Jan 22, 2021 16:01:16 GMT
|
|
|
|
Post by JHam on Jan 22, 2021 16:50:31 GMT
|
|
|
|
Post by magnus123 on Jan 22, 2021 19:24:50 GMT
Sounds interesting, although i lost almost always money with canadian stocks... But an uplisting to the Nasdaq could be a nice catalyst to move significantly higher. Risk / Reward ratio is really not bad.
|
|
|
|
Post by JHam on Jan 23, 2021 1:49:34 GMT
Sounds interesting, although i lost almost always money with canadian stocks... But an uplisting to the Nasdaq could be a nice catalyst to move significantly higher. Risk / Reward ratio is really not bad. I know what you mean. I believe this one could be different. They are the most US-like Canadian company I have seen. There is a real effort for them to become known to international investors. Apparently there is also big international demand for their product, since they don't use synthetics or anything toxic in it. It is all-natural and pure. Also, I really do like that Steve Grasso is involved and bullish on this company. From his appointment PR: www.cardiolrx.com/cardiol-therapeutics-appoints-cnbc-market-analyst-steven-grasso-as-business-advisor/Cardiol Therapeutics Appoints CNBC Market Analyst Steven Grasso as Business AdvisorOakville, ON – June 29, 2020 – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (“Cardiol” or the “Company”), a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol products for heart diseases, is pleased to announce that it has appointed Steven Grasso as Business Advisor to the Company.
Steven Grasso began his career on the floor of the New York Stock Exchange in 1993. He joined Stuart Frankel & Co. as an institutional sales trader in 1999. As Director of Institutional Sales for Stuart Frankel & Co., Steven has worked closely with some of the largest mutual funds, pension funds, insurance companies, and hedge funds in the world directly from the floor of the Stock Exchange. Over his 27-year career, Steven has actively participated in various Stock Exchange committees ranging from allocating new listings to designated market makers to developing standardized tests that the floor community uses for continuing education. Steven closely follows the Washington D.C./Markets connection, using his extensive Capitol Hill and SEC relationships to better inform his clients on policy changes and regulation.
Steven is perhaps best known for being a CNBC market analyst and is a regular on CNBC’s popular “Fast Money” show, which airs daily during the business week and has an average daily viewership that currently exceeds 250,000. Mr. Grasso also speaks at many traders’ conferences across the country on a regular basis, as well as business round tables with many influential leaders of industry where he addresses a broad range of market related issues, including the effects of regulation and the political process on equities.
As Business Advisor, Mr. Grasso will assist with raising Cardiol’s profile within the U.S. investment community. Steven has the ability to provide important introductions to Investors, Analysts, Investment Banks, and other key investment industry participants. He also has an extensive network of connections with senior management of many of the largest pharmaceutical and biotechnology companies in the world, which will be of assistance to the Company in achieving its commercial and business development objectives.
“We are pleased that Steve has agreed to join Cardiol as Business Advisor,” stated David Elsley, President and CEO of Cardiol Therapeutics. “We believe Mr. Grasso’s impressive background in the financial markets will be of tremendous benefit to our Company as we advance the development of important new therapies for life-threatening heart disease. We also believe Steve’s high profile within the financial media will serve to accelerate broad recognition of Cardiol’s market potential.
In connection with the appointment of Mr. Grasso and to support the alignment of his interests with the interests of Cardiol’s shareholders, David Elsley, Cardiol’s President and Chief Executive Officer, has agreed to grant him an option (the “Shareholder Option”) to acquire up to 250,000 Class A common shares (each a “Share”) owned by Mr. Elsley at a price of $2.58 per Share for a period of two years. Mr. Elsley will not receive any consideration in connection with the grant of the Shareholder Option. The Shareholder Option is in addition to an option grant by the Company under its Equity Compensation Plan. |
|
|
|
Post by JHam on Jan 23, 2021 10:44:18 GMT
Just posting some more DD as I find it. The more I read, the more I like the potential here. Glad to see that people are buying CBD products "irrespective of their cost", because Coralex is not cheap. It's listed at $300+ a bottle. There are far cheaper options on the market, but they are not as pure and contain synthetics in the formulation, which many consumers are trying to avoid. So you get what you pay for. I would love to see them bust into the US market for Coralex. The CEO said that's the plan. $9.3B market in 2020, expected to grow to $23.6B by 2025: www.grandviewresearch.com/industry-analysis/cannabidiol-cbd-marketCannabidiol has become the latest consumer trend, which is a result of the increasing number of social media influencers promoting the benefits of cannabis, marketing initiatives by the industry participants, and growing application areas. Subsequently increasing product options such as skincare, cosmetics, haircare, intimate lubricants, pharmaceuticals, gummies, pills, infused beverages, and other products are also driving the market for cannabidiol.
Increasing awareness about the therapeutic benefits of cannabidiol has influenced people to buy CBD based products, irrespective of their cost. Mainstream retailers are now focusing on selling CBD-based products, as these have a higher profit margin. Various health and wellness retailers such as CVS Health, Rite Aid, and Walgreens Boots Alliance have decided to sell CBD-based products. Moreover, CVS Health is planning to sell CBD topicals through its 800 stores, and Walgreens Boots Alliance is planning to sell CBD containing topicals in 1500 of its stores in the U.S.
On the other hand, the presence of stringent regulations and the high cost of CBD products are some of the major factors restraining the growth of the market for cannabidiol. Moreover, the absence of legalization programs in several Asian and African countries is another key factor impeding the growth of the CBD market.
...
The medical segment dominated the market in 2018, with a revenue share of 44.5%, and is expected to grow at a lucrative growth rate over the forecast period. The large share has attributed to factors such as rising use of CBD for medical conditions such as epilepsy, schizophrenia, chronic pain, sleep disorders, and symptoms of multiple sclerosis. Moreover, people suffering from chronic pain are now opting for CBD-based products to manage associated conditions, which is expected to fuel market growth over the forecast period.
The pharmaceutical segment is anticipated to witness the highest growth rate over the forecast period. Companies manufacturing CBD infused pharmaceuticals for treating various medical conditions such as epilepsy and multiple sclerosis (MS) symptoms are anticipated to boost the growth of this segment. Furthermore, major players such as Charlotte's Web; GW Pharmaceuticals plc; Isodiol International Inc.; and CannaHealth, are using cannabidiol for manufacturing soft gel capsules and tinctures are also influencing the growth of this segment.
In 2018, North America accounted for the largest market share and will continue to retain its leading position in the market. The increasing legalization of medical cannabis in independent states of the U.S., the liberalism of government regulations regarding the same, and an overall increase in the acceptance of cannabidiol for pharmaceutical, wellness, and personal use are some of the major factors driving the growth of the region. Furthermore, the implementation of the Farm Bill in the U.S., allowing hemp-derived CBD is also supporting the growth of the market in the region. Moreover, Canada has legalized the production and sale of both CBD and THC potent marijuana for medical purposes. Therefore, the availability of CBD based products in the country is also supporting the growth of the market in the region. |
|
|
|
Post by JHam on Jan 23, 2021 16:04:50 GMT
One thing about accumulating now. They can’t up-list to the NASDAQ until they cross the $4 threshold. That could take some effort. P1 AM data and Q1 Cortalex numbers could do the trick. My thesis for buying now is that I think once they are on the NASDAQ it could be to late to get in. Of course if data sucks, then it won’t really matter.
They are similar to INMB in that as it pertains to COVID, they are tackling inflammation of the endothelium (inner wall lining of the arteries). The difference is CDRL is targeting patients with pre-existing comorbidities, people who have a history of heart issues. So they aren’t really a hedge to INMB in that regard, but I like how they are going after inflammation.
Lastly, the bear thesis I have read so far is that CBD space is flooded with crap companies. You can buy it anywhere online or at regular brick and mortar shops. The key difference with CDRL though, that I think is being overlooked, is that they are targeting the pediatric (<25) and geriatric (>65) population, who cannot consume THC and who need pure forms of CBD.
Sorry for writing so much. It’s the best way to organize and log my thoughts. Feel free to ignore 😅
|
|
|
|
Post by JHam on Jan 23, 2021 16:30:58 GMT
Jimmy Mengel, who is a well known analyst for the cannabis sector, has CRDL as one of his top recommendations. technical420 has CRDL listed as one of their 10 cannabis stocks to watch in 2021: technical420.com/cannabis-article/10-cannabis-companies-to-be-watching-in-2021/2020 was a challenging year for the global economy and we are hoping that 2021 is a bounce back year for it. The COVID pandemic has put considerable pressure on companies, large and small, and the cannabis sector has not been unaffected by the spread of the virus.
Although cannabis was declared to be an essential industry in the US during the pandemic, consumer spending patterns have been impacted by the pandemic.
In the cannabis sector, we are seeing a major transition in the types of cannabis products that are preferred by consumers. During the last few years, we have noticed an increase in the number of consumers who are using vape pens or edibles instead of cannabis flower. This is a significant trend and we have been working to identify companies that are levered to this trend.
Today, we have highlighted 10 cannabis companies that we believe are poised to record strong growth in 2021. We are going to closely follow these operators in 2021 and believe that our readers need to be aware of these companies....
Cardiol Therapeutics Inc. (CRDL.TO) (CRTPF) is a clinical-stage biotechnology company that is focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Cardiol recently appointed Worldwide Clinical Trials as it contract research organization (CRO) ahead of its plan to initiate a Phase II/III clinical trial on high-risk patients who are hospitalized with COVID-19. Although the company’s recent trend has been to the downside, we believe that Cardiol represents a differentiated growth opportunity. |
|
|
|
Post by JHam on Jan 24, 2021 1:37:55 GMT
Acute myocarditis (AM), is an inflammatory heart condition caused by viral infection and is the leading cause of sudden cardiac death in young people. The CEO said in an interview that by being able to jump to a pivotal P2/3 COVID trial with 422 patients, they’ll essentially save 2-3 years time and money. Again, similar to INMB (and many others I’m sure) in that way.
|
|
|
|
Post by JHam on Jan 24, 2021 2:05:36 GMT
There have been several scientific studies done since, but this pre-clinical study reported in JACC in 2010 is the one that set the backdrop for CRDL to go all in: www.jacc.org/doi/full/10.1016/j.jacc.2010.07.033(excerpt from the discussion) Treatment with CBD (Supplemental Fig. 1) was able to attenuate the oxidative-nitrative stress (decreased the myocardial ROS generation and expression of p22phox, p67phox, gp91phox, restored glutathione content and SOD activity, decreased 3-NT formation) and alterations of the pro-survival (Akt) and stress signaling (p38, p38α, JNK) pathways in diabetic hearts. It also attenuated the NF-κB activation, expression of iNOS, TNFα, and ICAM-1, cell death, and fibrosis in diabetic myocardium, and improved the associated characteristic functional alterations. Importantly, CBD treatment was able to attenuate/reverse (although to a lesser extent) some of the discussed diabetes-induced myocardial biochemical and functional changes after the establishment of diabetic cardiomyopathy with fibrosis (Online Figs. 2 to 5). The CBD treatment also attenuated the HG-induced increased reactive oxygen and nitrogen species generation, NF-κB activation, and cell death in primary human cardiomyocytes (Online Figs. 6 to 8).
The discussed beneficial effects of CBD could be explained in part by its potent antioxidant properties, which was first suggested by the Nobel Prize winner Dr. Julius Axelrod (31). In the Axelrod study, CBD was more protective against glutamate-induced neurotoxicity than any of the well-know antioxidants (e.g., ascorbate or α-tocopherol), indicating additional cytoprotective effects of CBD beyond its potent antioxidant properties (31). Indeed, our recent results suggest that CBD may exert potent effects on key pro-inflammatory pathways such as NF-κB and on pro-survival signaling such as Akt in vivo, which is most likely not related to its antioxidant effect. This is also supported by observations that CBD decreases inflammation in models in which conventional antioxidants are not very effective (e.g., in arthritis [20,32]), as well as by recent studies demonstrating that CBD is a potent inhibitor of bacterial lipopolysaccharide-activated NF-κB proinflammatory pathway in microglia cells (33). These results are also in support of the emerging role of the inflammation in the development and progression of diabetic cardiomyopathy (9,11,15,30).
Collectively, our results strongly suggest that CBD may have tremendous therapeutic potential in the treatment of diabetic cardiovascular and other complications by attenuating diabetes-induced oxidative/nitrative stress, inflammation, cell death, and fibrotic pathways. |
|
|
|
Post by JHam on Jan 29, 2021 18:39:16 GMT
Just sold out of this today for a massive 2% profit. I still like the potential here, but I wasn’t anticipating both QUIK and OBLG to stumble the way the have the past few days. Wanted to make sure to not lose money here in the event QUIK and OBLG continue to dip down.
|
|
|
|
Post by JHam on Jan 29, 2021 18:39:36 GMT
Definitely looking to get back in here at some point.
|
|
|
|
Post by JHam on Feb 3, 2021 15:19:53 GMT
Crap, this is taking off today. $2.85 at the moment. Was hoping to get back back in before this kind of movement. Wondering if data is about to hit.
|
|
|
|
Post by JHam on Feb 4, 2021 1:53:05 GMT
This one hit $3.10 today. If news must be coming. I hate it when the stocks I follow all start to run at the same time.
|
|
|
|
Post by JHam on Feb 11, 2021 4:04:29 GMT
This closed the day at $3.74 but actually touched $3.95. The bears were saying there was no way they’d be able to meet the $4 NASDAQ up-list threshold unless they did a r/s. There on the cusp now and looking like they might just be able to do it. I sold at $2.58, so I missed about a 50% run-up to the current pps. Thankfully I’ve made up for it elsewhere so I’m not as bothered by having to buy over $4 of it gets there. Still lots of room to grow as things are just getting started here.
|
|
|
|
Post by JHam on Feb 17, 2021 23:55:52 GMT
Closed above $4 today ($4.08). Extremely bullish that they were able to do this w/o having To do a reverse split. If they can hold this pps for a bit they could execute the NASDAQ up-list. Looking to get back in here again soon.
|
|
|
|
Post by magnus123 on Mar 10, 2021 12:27:00 GMT
|
|
|
|
Post by JHam on Mar 10, 2021 12:51:03 GMT
Nice catch! Not sure how I missed this! |
|
